Keywords
Multiple Myeloma ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

348 Search results.

Eligibility Multiple Myeloma NCT02497378

- 5/15/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT02497378

Eligibility Multiple Myeloma NCT02462525

- 5/15/19 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT02462525

Eligibility Multiple Myeloma NCT02416206

- 5/15/19 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT02416206

Eligibility Multiple Myeloma NCT02402725

- 5/15/19 - 1 form, 2 itemgroups, 30 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT02402725

Eligibility Multiple Myeloma NCT02400242

- 5/14/19 - 1 form, 1 itemgroup, 14 items, 1 language
Itemgroup: Criteria
Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT02400242

Eligibility Multiple Myeloma NCT02315716

- 5/14/19 - 1 form, 2 itemgroups, 29 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Carfilzomib/Cyclophosphamide/Dexamethasone With Maintenance Carfilzomib in Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT02315716

Eligibility Multiple Myeloma NCT02289222

- 5/13/19 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT02289222

Eligibility Multiple Myeloma NCT02206425

- 5/13/19 - 1 form, 1 itemgroup, 31 items, 1 language
Itemgroup: Criteria
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients; ODM derived from: https://clinicaltrials.gov/show/NCT02206425

Eligibility Multiple Myeloma NCT02076009

- 5/13/19 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT02076009

Eligibility Multiple Myeloma NCT01998971

- 5/13/19 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT01998971

Safety and Activity of SRT501 Alone or in Combination with Bortezomib in Patients with Multiple Myeloma NCT00920556 - SRT501, Monotherapy, Cycle __ Day 21 - Physical Examination; Vital Signs; 12-Lead ECG; Hematology; Clinical Chemistry, Coagulation and Electrolytes; Urinalysis; Urinalysis microscopy results; Serum beta-hCG Pregnancy Test; Radiographic Assessment; Disease Marker Assessment; Disease Response; Study Treatment Compliance (Return); New Adverse Events and Concomitant Treatment

- 3/10/19 - 1 form, 23 itemgroups, 109 items, 1 language
Itemgroups: Administrative, Visit Date, Was a physical examination performed?, Physical Examination, Vital Signs, 12-Lead ECG, ECG Result, ECG Findings, Hematology, Hematology , Clinical Chemistry, Coagulation and Electrolytes, Clinical Chemistry, Coagulation and Electrolytes , Urinalysis dipstick results, Urinalysis microscopy results, Urinalysis microscopy results , Serum beta-hCG Pregnancy Test, Radiographic Assessment, Radiographic Assessment , Disease Marker Assessment , Disease Marker Assessment , Disease Response, Study Treatment Compliance (Return) , New Adverse Events and Concomitant Treatment
Study ID: 113222 Clinical Study ID: 113222 Study Title: A Phase II, Open Label, Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination with Bortezomib in Patients with Multiple Myeloma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00920556 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name:5.0g SRT501 Trade Name: Bortezomib Study Indication: Multiple Myeloma

Safety and Activity of SRT501 Alone or in Combination with Bortezomib in Patients with Multiple Myeloma NCT00920556 - Non Visit - Adverse Events; Prior and Concomitant Medications; Comments; Protocol Deviations; Data Verification

- 3/10/19 - 1 form, 10 itemgroups, 36 items, 1 language
Itemgroups: Administrative, Adverse Events, Adverse Events, Prior and Concomitant Medications, Prior and Concomitant Medications , Are any comments required? , Comments, Did the subject deviate from the procedures as described in the protocol?, Protocol Deviations, Data Verification
Study ID: 113222 Clinical Study ID: 113222 Study Title: A Phase II, Open Label, Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination with Bortezomib in Patients with Multiple Myeloma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00920556 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name:5.0g SRT501 Trade Name: Bortezomib Study Indication: Multiple Myeloma